Table 1 Fourteen microarray-based human lung cancer microRNA expression profiling studies (lung cancer tissue versus normal)
First author (reference) | Year | Lung cancer patients | Differentially expressed miRNAs | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Origin | Period | Cancer type | Clinical Stage | No. of collected tissue samples (cancer/normal) | Platform | Cut-off criteria | Total | Up-regulated features | Down-regulated features | ||
Boeri [19] | 2011 | Italy | Jun 2000 to Jun 2006 | Lung cancer | Satge I to IV (Stage I 60%) | 52 (28/24) | The miRNA microarray (Ohio State University, version 2.0) | P < 0.001 | 56 | 6† | 4† |
Dacic [20] | 2010 | USA (Pittsburgh) | NR | ADC | NR | 12 (6/6) | FlexmiR human microRNA pool (Version 8, Exiqon, Vedbaek, Denmark) | FC > 20 | 7 | 4 | 3 |
Gao [21] | 2010 | China (Jiangsu, First Affiliated Hospital of Nanjing Medical University) | Apr 2008 to Sep 2008 | NSCLC | NR | 16 (8/8) | miRCURY™ LNA microRNA Arrays (version 10.0, Exiqon, Vedbaek, Denmark) | FC > 2, P < 0.05 | 27 | 9 | 18 |
Apr 2008 | SCC [Ref 33] | NR | 8 (4/4) | FC > 2 | 31 | 7 | 23 | ||||
Jang [22] | 2012 | USA (Minnesota) | Jan 1997 to Sep 2008 | ADC | Stage I to IV (Stage I 68.0%) | 206 (103/103) | Illumina MicroRNA Profiling | FC > 1.5, P < 0.01, DR < 0.05 | 20 | 10 | 10 |
Ma [23] | 2011 | China (Zhejiang) | NR | NSCLC (SCC:3; ADC:3) | Stage I to IV (Stage I 16.7%) | 12 (6/6) | Illuminia Technologies “humanMI_V2” | FDR <0.1 | 1 | 1 | 0 |
Raponi [24] | 2009 | USA (Michigan) | Oct 1991 to Jul 2002 | SCC | Stage I to IV (Stage I 55%) | 71 (61/10) | Ambion mirVana Bioarray (version 2.0) | Signal intensity (log2) >6 in at least one group | 15 | 13 | 2 |
Seike [25] | 2009 | USA (Baltimore: 15; Minnesota:7); Japan (Hamamatsu: 6) | 2000 to 2004 | NSCLC (ADC around 78%) | Stage I to IV (Stage I 75%) | 56 (28/28) | The miRNA microarray (Ohio State University, version 3.0) | P < 0.01, FDR <0.15 | 18 | 5 | 13 |
Tan [26] | 2011 | China (Beijing) | 2000 to 2002 | SCC | NR | 68 (34/34) | CapitalBio platform (CapitalBio Corp.) | Significance analysis of microarray | 22 | 12 | 10 |
Võsa [27] | 2011 | Estonia (Tartu) | 2002 to 2008 | NSCLC (SCC:18; ADC:20) | Stage I/II (Stage I 92%) | 65 (38/27) | Illumina MicroRNA Profiling BeadChip | FC > 2, P < 0.01 | 60 | 31 | 29 |
Wang [28] | 2011 | China (Jiangsu, Nanjing Chest Hospital) | 2006 to 2008 | NSCLC (SCC:7; ADC:16) | NR | 46 (23/23) | μParaflo microfluidic chip technology (Atactic Technologies, Houston, TX, USA) | FC > 5, P < 0.01 | 40 | 27 | 13 |
Xing [29] | 2010 | USA (Baltimore) | Mar 2000 to Jun 2003 | SCC | Stage I | 30 (15/15) | GeneChipR miRNA Array (Affymetrix, Santa Clara, CA, USA) | FC > 1.5, P < 0.01 | 25 | 7 | 18 |
Yanaihara [30] | 2006 | USA (Baltimore) | 1990 to 1999 | NSCLC (SCC:39; ADC:65,) | Stage I to IV (Stage I 62.5%) | 208 (104/104) | The miRNA microarray Chip (TJU version 1.1) | P < 0.001 | 43 | 15 | 28 |
SCC | 78 (39/39) | 16 | 10 | 6 | |||||||
ADC | 130 (65/65) | 17 | 5 | 12 | |||||||
Yang [31] | 2010 | China (Shaanxi) | NR | SCC | NR | 6 (3/3) | miRCURY™ LNA array (version 10.0, Exiqon, Vedbaek, Denmark) | FC > 1.5, P < 0.05 | 9 | 2 | 7 |
Yu [32] | 2010 | USA (Baltimore) | NR | ADC | Stage I | 40 (20/20) | Taqman human miRNA array A (System Biosciences, Mountain View, CA) | FC > 1.5, P < 0.01 | 20 | 11 | 9 |